Correlation between Therapeutic Efficacy of CD34⁺ Cell Treatment and Directed In Vivo Angiogenesis in Patients with End-Stage Diffuse Coronary Artery Disease

Table 2

Univariate logistic regression models for the association between significant variables and improved angiographic findings.

Univariate logistic regression model
Variables	OR	95% CI	value
Age	1.01	(0.92–1.12)	0.791
Gender	1.86	(0.40–8.69)	0.432
Body height	1.07	(0.96–1.20)	0.237
Body weight	1.02	(0.96–1.09)	0.557
Body mass index	1.04	(0.86–1.25)	0.706
Hypertension	0.46	(0.04–4.98)	0.518
Diabetes mellitus	1.67	(0.28–10.09)	0.578
History or current smoking	2.00	(0.44–9.10)	0.370
Total cholesterol	0.99	(0.97–1.01)	0.242
Low-density lipoprotein	1.00	(0.98–1.03)	0.808
High-density lipoprotein	0.96	(0.89–1.03)	0.236
Previous stroke	1.43	(0.22–9.38)	0.710
Old myocardial infarction	1.00	(0.14–7.10)	1.000
History of CABG	0.70	(0.16–3.17)	0.643
Diffuse multivessel disease	—	—	—
Diffuse triple vessel disease	1.00	(0.14–7.10)	1.000
Previous PCI	0.57	(0.13–2.50)	0.458
Aspirin/clopidogrel therapy	—	—	—
β-Blocker therapy	0.77	(0.09–27.36)	0.767
Stain therapy	2.50	(0.51–12.35)	0.261
ARB/ACEI therapy	1.17	(0.21–6.48)	0.860
Creatinine level	3.79	(0.43–33.72)	0.232
Creatinine clearance rate	0.99	(0.95–1.02)	0.525
Stage III–IV CKD	0.89	(0.20–3.91)	0.880
Before G-CSF treatment
KDR^+/CD34^+/CD45^−	2.26	(0.02–319.53)	0.747
CD133^+/CD34^+/CD45^−	0.001	(0.00–118.39)	0.240
CD34^+	0.85	(0.39–1.89)	0.696
After G-CSF treatment
KDR^+/CD34^+/CD45^−	0.58	(0.16–2.13)	0.409
CD133^+/CD34^+/CD45^−	0.46	(0.14–1.49)	0.197
CD34^+	0.85	(0.56–1.28)	0.430
DIVAA ratio	3.12	(1.14–8.55)	0.027

Defined significant at .